Tangram Therapeutics submitted a clinical trial application to the U.K. Medicines and Healthcare products Regulatory Agency to start a phase I/II study of TGM‑312 for metabolic dysfunction‑associated steatohepatitis (MASH). The application seeks authorization for first‑in‑human dosing to evaluate safety, pharmacokinetics and early activity in patients with steatohepatitis and associated metabolic dysfunction. Tangram’s CTA represents a step toward clinical validation of a candidate addressing a high‑unmet‑need NASH/MASH population where regulatory pathways and endpoints remain evolving. If cleared, the study will position TGM‑312 among an expanding cohort of metabolic and anti‑fibrotic therapies advancing through early clinical testing. Clarification: MASH (metabolic dysfunction‑associated steatohepatitis) is a form of fatty‑liver disease characterized by inflammation and fibrosis linked to metabolic drivers.